Background
Methods
Patient background
Ethics statement
Immunohistochemistry
Immunohistochemical evaluation
Statistical analysis
Results
Clinical characteristics
Parameters (n = 30) | Number of patients (%) |
---|---|
Age (years old) | 62 (31–80) |
Degree of progress | |
Locally advanced/visceral metastases | 10 (33.3%)/20 (66.7%) |
Stage | |
Stage IIIC/stage IV/recurrence | 4 (13.3%)/11 (36.7%)/15 (50.0%) |
Site of metastases | |
Lung/bone/liver/brain/lymph node/soft tissue | 11 (36.7%)/12 (40.0%)/7 (23.3%)/3 (10.0%)/12 (40.0%)/11 (36.6%) |
Treatment line | |
First/other | 17 (56.7%)/13 (43.3%) |
ER | |
Negative/positive | 18 (60.0%)/12 (40.0%) |
PgR | |
Negative/positive | 20 (66.7%)/10 (33.3%) |
Ki67 | |
Negative/positive | 16 (55.2%)/14 (44.8%) |
CD8 | |
Negative/positive | 21 (70.0%)/9 (30.0%) |
FOXP3 | |
Negative/positive | 15 (50.0%)/15 (50.0%) |
CFR | |
Low/high | 15 (50.0%)/15 (50.0%) |
PD1 | |
Negative/positive | 14 (46.7%)/16 (53.3%) |
PD-L1 | |
Negative/positive | 19 (63.3%)/11 (36.7%) |
CD163 | |
Negative/positive | 15 (50.0%)/15 (50.0%) |
PTEN | |
Negative/positive | 17 (56.7%)/13 (43.3%) |
LAG3 | |
Negative/positive | 20 (66.7%)/10 (33.3%) |
Association of each immune-related protein with ORR, PFS, and OS
Parameters | Responders (n = 25) | Non-responders (n = 5) | p value |
---|---|---|---|
Age at treatment | |||
≤ 62 vs > 62 | 12 (48.0%) vs 13 (52.0%) | 3 (60.0%)/2 (40.0%) | 0.638 |
Degree of progress | |||
Locally advanced vs visceral metastases | 9 (36.0%)/16 (64.0%) | 1 (20.0%)/4 (80.0%) | 0.505 |
Stage | |||
IIIC or IV vs recurrence | 12 (48.8%)/13 (52.0%) | 3 (60.0%)/2 (40.0%) | 0.638 |
ER | |||
Negative vs positive | 16 (64.0%)/9 (36.0%) | 2 (40.0%)/3 (60.0%) | 0.334 |
PgR | |||
Negative vs positive | 17 (68.0%)/8 (32.0%) | 3 (60.0%)/2 (40.0%) | 0.740 |
Ki67 | |||
Negative vs positive | 14 (56.0%)/11 (44.4%) | 2 (40.0%)/3 (60.0%) | 0.529 |
Treatment line | |||
First vs other | 16 (64.0%)/9 (36.0%) | 1 (20.0%)/4 (80.0%) | 0.074 |
CD8 | |||
Negative vs positive | 16 (64.0%)/9 (36.0%) | 5 (100.0%)/0 (0.0%) | 0.116 |
FOXP3 | |||
Negative vs positive | 12 (48.8%)/13 (52.0%) | 3 (60.0%)/2 (40.0%) | 0.638 |
CFR | |||
Low/high | 10 (40.0%)/15 (60.0%) | 5 (100.0%)/0 (0.0%) | 0.013 |
PD1 | |||
Negative vs positive | 11 (44.0%)/14 (56.0%) | 3 (60.0%)/2 (40.0%) | 0.529 |
PD-L1 | |||
Negative vs positive | 17 (68.0%)/8 (32.0%) | 2 (40.0%)/3 (60.0%) | 0.250 |
CD163 | |||
Negative vs positive | 12 (48.8%)/13 (52.0%) | 3 (60.0%)/2 (40.0%) | 0.638 |
PTEN | |||
Negative vs positive | 13 (52.0%)/12 (48.8%) | 4 (80.0%)/1 (20.0%) | 0.264 |
LAG3 | |||
Negative vs positive | 16 (64.0%)/9 (36.0%) | 4 (80.0%)/1 (20.0%) | 0.505 |
Parameters | Univariate | Multivariate | ||||
---|---|---|---|---|---|---|
Hazard ratio | 95% CI | p value | Hazard ratio | 95% CI | p value | |
Age at treatment | ||||||
≤ 62 vs > 62 | 1.271 | 0.395–4.096 | 0.680 | |||
Degree of progress | ||||||
Locally advanced vs visceral metastases | 0.934 | 0.293–3.505 | 0.912 | |||
Stage | ||||||
IIIC or IV vs recurrence | 1.260 | 0.402–4.263 | 0.692 | |||
ER | ||||||
Negative vs positive | 1.581 | 0.494–5.063 | 0.431 | |||
PgR | ||||||
Negative vs positive | 0.925 | 0.246–2.948 | 0.898 | |||
Ki67 | ||||||
Negative vs positive | 1.066 | 0.333–3.410 | 0.912 | |||
Treatment line | ||||||
First vs other | 1.449 | 0.452–4.643 | 0.522 | |||
CD8 | ||||||
Negative vs positive | 0.162 | 0.009–0.837 | 0.027 | 0.333 | 0.017–2.349 | 0.292 |
FOXP3 | ||||||
Negative vs positive | 0.513 | 0.137–1.632 | 0.263 | |||
CFR | ||||||
Low/high | 0.195 | 0.043–0.664 | 0.008 | 0.336 | 0.062–1.455 | 0.149 |
PD1 | ||||||
Negative vs positive | 0.751 | 0.234–2.404 | 0.620 | |||
PD-L1 | ||||||
Negative vs positive | 3.147 | 0.994–10.754 | 0.051 | 1.441 | 0.400–5.768 | 0.582 |
CD163 | ||||||
Negative vs positive | 0.932 | 0.291–2.992 | 0.904 | |||
PTEN | ||||||
Negative vs positive | 0.814 | 0.240–2.556 | 0.725 | |||
LAG3 | ||||||
Negative vs positive | 0.364 | 0.056–1.386 | 0.149 |